Search

Your search keyword '"Johns, Amber L"' showing total 85 results

Search Constraints

Start Over You searched for: Author "Johns, Amber L" Remove constraint Author: "Johns, Amber L"
85 results on '"Johns, Amber L"'

Search Results

51. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation

52. beta III-Tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer

53. ICGC-ARGO precision medicine: familial matters in pancreatic cancer

54. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial

55. Personalising pancreas cancer treatment: When tissue is the issue

56. βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer

57. International network of cancer genome projects

58. Somatic Point Mutation Calling in Low Cellularity Tumors

59. Abstract 1156: A molecular pre-operative prognostic nomogram for resectable pancreatic cancer.

60. Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater

61. Clinical and molecular characterization of HER2 amplified-pancreatic cancer

62. qpure: A Tool to Estimate Tumor Cellularity from Genome-Wide Single-Nucleotide Polymorphism Profiles

63. Abstract B64: A molecular preoperative prognostic nomogram for resectable pancreatic cancer.

64. Margin Clearance and Outcome in Resected Pancreatic Cancer

67. Ampullary Cancers Harbor ELF3Tumor Suppressor Gene Mutations and Exhibit Frequent WNTDysregulation

68. Returning individual research results for genome sequences of pancreatic cancer.

69. HNF4Aand GATA6Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

70. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

72. Sex differences in oncogenic mutational processes

73. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

74. Pan-cancer analysis of whole genomes

75. Return of individual research results from genomic research: A systematic review of stakeholder perspectives

76. Sex differences in oncogenic mutational processes

77. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

78. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

79. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis

80. βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer

81. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status.

82. DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association.

83. Lost in translation: returning germline genetic results in genome-scale cancer research.

84. βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer.

85. Personalising pancreas cancer treatment: When tissue is the issue.

Catalog

Books, media, physical & digital resources